Weight problems and consuming issues have historically been handled as separate areas of healthcare – however the speedy rise of GLP-1 medicines is more and more bringing the 2 collectively.
Adelaide College researchers say the rising use of medicines reminiscent of Ozempic and Mounjaro is highlighting an under-recognzed overlap between the circumstances – and elevating necessary questions on who may benefit and who could also be in danger.
Rising preliminary proof suggests GLP-1 medicines might scale back binge-eating behaviors in some folks, whereas questions stay about whether or not their appetite-suppressing results may probably pose dangers for some folks with consuming issues.
Professor Gemma Sharp, a medical psychologist and a global skilled in consuming issues, physique picture and weight issues, stated the standard divide not displays the fact of affected person care.
“For too lengthy we have handled weight problems and consuming issues as if they’re opposing well being circumstances, however they really have extra in widespread than many individuals notice,” Prof Sharp stated.
“Usually, when folks consider an consuming dysfunction, they image somebody who could be very skinny. However that is one of many largest misconceptions on this discipline.
“In reality, most individuals dwelling with an consuming dysfunction aren’t underweight, and plenty of go undiagnosed as a result of the main focus is usually on weight reasonably than recognising the consuming dysfunction itself.
“As medicines reminiscent of Ozempic and Mounjaro develop into extra broadly used, the necessity to take into account weight problems and consuming issues collectively is turning into more and more troublesome to disregard.”
The potential overlap is critical. In Australia, about one in three adults reside with weight problems. Round 5% of Australians (round 1.1 million folks) expertise an consuming dysfunction.
Whereas early proof suggests GLP-1 medicines might assist some folks, researchers say they’re just one a part of the answer.
“The problem is not merely the medicines themselves – it is making certain they’re used as a part of evidence-based, multidisciplinary care,” Prof Sharp stated.
“Consuming issues aren’t one illness, so there will not be one reply. And whereas GLP-1 medicines might develop into an necessary therapy choice for some folks, they’re just one piece of the puzzle.
“The precedence now’s figuring out which sufferers are more than likely to learn, which sufferers are at best danger of hurt, and making certain applicable screening, monitoring and multidisciplinary care develop into a part of routine prescribing.
“The longer term is not selecting between treating weight problems and treating consuming issues. It is recognising that many individuals expertise each and constructing care round the entire individual – not merely the quantity on the scales.”
Points like these are mentioned by the Consortium for Analysis in Consuming Issues (CoRe-ED).
Established by Professor Sharp, CoRe-ED is a first-of-its-kind worldwide unbiased charity initiative bringing collectively the varied views wanted to sort out complicated points in consuming issues – together with researchers, clinicians, folks with lived expertise, advocates, not-for-profit organisations and trade, in addition to companions working in associated fields reminiscent of weight problems.
GLP-1 medicines are an ideal instance of why CoRe-ED was established.
Advanced points like this require us to carry completely different voices and disciplines to the identical desk, reasonably than approaching weight problems and consuming issues in isolation.”
Professor Gemma Sharp, medical psychologist, Adelaide College
